BRAF and melanoma: Since ABL1/2 play important roles in driving melanoma progression and are activated by ERK pathway components (BRAF, ERK) in BRAF-mutant melanomas [22], we examined whether their activities are elevated during MEKi resistance in NRAS-driven melanomas.